Jean-Charles Soria to Antineoplastic Agents
This is a "connection" page, showing publications Jean-Charles Soria has written about Antineoplastic Agents.
Connection Strength
3.125
-
Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? Eur J Cancer. 2020 09; 137:235-239.
Score: 0.271
-
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 01 11; 378(2):113-125.
Score: 0.225
-
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Invest New Drugs. 2018 08; 36(4):619-628.
Score: 0.224
-
Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. Eur J Cancer. 2017 11; 85:155-157.
Score: 0.222
-
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541.
Score: 0.217
-
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512.
Score: 0.216
-
Otorhinolaryngological Toxicities of New Drugs in Oncology. Adv Ther. 2017 04; 34(4):866-894.
Score: 0.214
-
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017 03 13; 15(1):55.
Score: 0.214
-
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
Score: 0.212
-
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer. 2011 Oct; 47(15):2249-55.
Score: 0.142
-
Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discov. 2021 06; 11(6):1336-1344.
Score: 0.071
-
Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med. 2020 06; 8(6):542-544.
Score: 0.066
-
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? Br J Cancer. 2018 10; 119(8):937-939.
Score: 0.060
-
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
Score: 0.059
-
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. J Clin Oncol. 2018 10 20; 36(30):3007-3014.
Score: 0.058
-
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 05; 19(5):649-659.
Score: 0.058
-
Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors. Arch Cardiovasc Dis. 2018 Apr; 111(4):285-296.
Score: 0.058
-
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Eur J Cancer. 2018 03; 92:1-10.
Score: 0.057
-
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
Score: 0.056
-
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017 12; 87:122-130.
Score: 0.056
-
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
Score: 0.055
-
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. Eur J Cancer. 2017 09; 83:194-202.
Score: 0.055
-
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
Score: 0.055
-
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clin Cancer Res. 2017 Sep 15; 23(18):5366-5373.
Score: 0.055
-
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Invest New Drugs. 2018 02; 36(1):62-74.
Score: 0.054
-
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer Treat Rev. 2017 Apr; 55:83-95.
Score: 0.054
-
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
Score: 0.014
-
[Hodgkin lymphoma: Current and future therapeutic strategies]. Bull Cancer. 2018 Jan; 105(1):81-98.
Score: 0.014
-
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs. 2017 06; 28(5):540-545.
Score: 0.014